highly variable drugs-Cmax [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-11-19 18:04 (175 d 02:23 ago) – Posting: # 22069
Views: 805

(edited by wienui on 2020-11-20 07:13)

Hi nuka & Helmut,

» According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
» But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
» Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Unfortunately, we come back again to this point. Although the GCC GL is adopted from the EMA GL,
but the upper cap of scaling is about only 39% and not 50%!!!!
At the moment, I think you could have a good chance under the conditions that your BE study is demonstrated in a replicate design and that the high within-subject variability for Cmax not caused by outliers.

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,460 posts in 4,486 threads, 1,511 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time: Thursday 21:28 CEST (Europe/Vienna)

Nothing in the world is more dangerous
than sincere ignorance
and conscientious stupidity.    Martin Luther King, Jr.

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5